Community-Acquired Bacterial Pneumonia – Epidemiology – Mature Markets Data

Clarivate Epidemiology’s coverage of community-acquired bacterial pneumonia (CABP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the event rate of CABP for each country, as well as annualized event counts projected to the national population.

Clarivate Epidemiology’s CABP forecast will answer the following questions:

  • Of all people diagnosed with CABP, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CABP over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of events for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following CABP subpopulations:

  • Diagnosed inpatient events by drug-treatment status.
  • Diagnosed outpatient events by drug-treatment status.